Jason Pogue, PharmD, BCPS, BCIDP, contextualizes preliminary data looking at this trial and other extended-spectrum beta-lactamase (ESBL) studies, which reopens the debate around carbapenem-sparing treatment options.
|Videos|May 30, 2017
Can the Influenza Vaccine Be the Key to Reducing Antibiotic Resistance?
Author(s)Contagion Editorial Staff
Lauri A. Hicks, DO, discusses keys to reducing antibiotic resistance.
Advertisement
Lauri A. Hicks, DO, Director, Office of Antibiotic Stewardship, Centers for Disease Control and Prevention, discusses keys to reducing antibiotic resistance.
Interview Transcript (slightly modified for readability)
“I think there are certainly
A good example is getting the flu vaccine. A good proportion of the population doesn’t get the flu vaccine each year, but it is one of the best ways to protect yourself from getting the flu. Even though the flu is a virus and is not caused by a bacteria and antibiotics don’t treat viruses, a lot of people with [the] flu end up getting an antibiotic.
I think some of the basic steps related to protecting the natural resource of antibiotics includes just taking some personal actions to protect ourselves from getting infections.”
Advertisement
Related to this article
Resistance-guided testing targeting a single gene mutation could let clinicians safely reintroduce ciprofloxacin for the majority of gonorrhea cases still susceptible to it, sparing ceftriaxone as resistance climbs worldwide. Lao-Tzu Allan-Blitz, MD, MPH, offers insights into his work in this area.
Lori Handy, MD, provides guidance in these areas including presentation before rash onset, when patients should be considered for the inpatient setting, and what treatment looks like.
IDSA/ESCMID panel member Henry Chambers, MD, explains why the new S aureus bacteremia guidance replaces the complicated vs uncomplicated label with risk stratification, and how the statements are akin to the stages of cancer in guiding treatment decisions associated with this bacteremia.
Staphylococcus aureus Bacteremia (SAB) causes significant morbidity and globally is the leading cause of death from bloodstream infection. This month, the IDSA and ESCMID released 7 consensus statements to assist in managing individuals with SAB. This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline. Here is a closer look at Consensus Statement 2: Follow-up Blood Cultures.
With a significant increase in rabies exposures this year, Rodney Rohde, PhD, talks about seeking medical attention after animal interactions as well as clinical treatment when people have been bit or scratched.
Widespread antimicrobial use disrupts vital microbial communities that regulate Earth’s biogeochemical cycles, driving antimicrobial resistance, worsening human and environmental health, and significantly contributing to climate change.
New data from the PETERPEN trial suggest that piperacillin-tazobactam may be noninferior to meropenem for early clinical outcomes in select patients with ESBL bloodstream infections, but carbapenems remain the standard of care until final mortality results are available and fully analyzed.
Advertisement
Advertisement
Trending on Contagion Live
1
New IDSA/ESCMID S aureus Bacteremia Consensus Statements: a Risk Stratification Framework
2
Measles Update: October 2, 2026
3
FAQ: Rising Rabies Exposure Calls PEP Decisions Back in Focus
4
Clinical Considerations for Measles: Presentation, Treatment, and Hospitalization
5